136 related articles for article (PubMed ID: 2140282)
1. Testicular histology after treatment with LH-RH analogue for carcinoma of the prostate.
Johansen TE; Ogreid P; Kjellevold K; Blom P
Br J Urol; 1990 Apr; 65(4):376-8. PubMed ID: 2140282
[TBL] [Abstract][Full Text] [Related]
2. U.K. trials of treatment for M1 prostatic cancer. The LH-RH analogue Zoladex vs. orchidectomy.
Ryan PG; Peeling WB
Am J Clin Oncol; 1988; 11 Suppl 2():S169-72. PubMed ID: 2977272
[TBL] [Abstract][Full Text] [Related]
3. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
[TBL] [Abstract][Full Text] [Related]
4. Response to orchiectomy following Zoladex therapy for metastatic prostate carcinoma.
Silver RI; Straus FH; Vogelzang NJ; Kellman H; Chodak GW
Urology; 1991 Jan; 37(1):17-21. PubMed ID: 1702566
[TBL] [Abstract][Full Text] [Related]
5. Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy.
Grant JB; Ahmed SR; Shalet SM; Costello CB; Howell A; Blacklock NJ
Br J Urol; 1986 Oct; 58(5):539-44. PubMed ID: 2946356
[TBL] [Abstract][Full Text] [Related]
6. Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist.
Ward JA; Robinson J; Furr BJ; Shalet SM; Morris ID
Cancer Res; 1990 Feb; 50(3):568-74. PubMed ID: 2137024
[TBL] [Abstract][Full Text] [Related]
7. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
[TBL] [Abstract][Full Text] [Related]
8. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.
Kaisary AV; Tyrrell CJ; Peeling WB; Griffiths K
Br J Urol; 1991 May; 67(5):502-8. PubMed ID: 1828183
[TBL] [Abstract][Full Text] [Related]
9. Pituitary hyperplasia after goserelin (LHRH-analogue) therapy.
Radner H; Pummer K; Lax S; Wandschneider G; Höfler H
Neuropathol Appl Neurobiol; 1991 Feb; 17(1):75-81. PubMed ID: 1647501
[TBL] [Abstract][Full Text] [Related]
10. Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. II. Endocrinology and histology of the testis.
Huhtaniemi I; Nikula H; Parvinen M; Rannikko S
J Androl; 1987; 8(6):363-73. PubMed ID: 3123446
[TBL] [Abstract][Full Text] [Related]
11. Influence of continuous luteinizing hormone-releasing hormone agonist treatment on steroidogenic enzymes in the human testis.
Petersson F; Hammar M; Mathson K; Hjertberg H; Varenhorst E
Scand J Urol Nephrol; 1987; 21(4):267-71. PubMed ID: 2965409
[TBL] [Abstract][Full Text] [Related]
12. A comparison between surgical orchidectomy and the LHRH agonist 'Zoladex' (ICI 188630) in the treatment of metastatic cancer of the prostate.
Peeling WB
Prog Clin Biol Res; 1989; 303():41-5. PubMed ID: 2528738
[No Abstract] [Full Text] [Related]
13. Effects of long term GnRH analogue treatment on hormone levels and spermatogenesis in patients with carcinoma of the prostate.
Lunglmayr G; Girsch E; Meixner EM; Viehberger G; Bieglmayer C
Urol Res; 1988; 16(4):315-9. PubMed ID: 2972102
[TBL] [Abstract][Full Text] [Related]
14. Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H).
Geldof AA; de Voogt HJ; Rao BR
Prostate; 1987; 11(3):281-90. PubMed ID: 2960958
[TBL] [Abstract][Full Text] [Related]
15. A comparison between surgical orchidectomy and LH-RH analogue ('Zoladex', ICI 118,630) in the treatment of advanced prostatic carcinoma--a multi-centre clinical study.
Kaisary AV; Ryan PG; Turkes A; Peeling WB; Griffiths K
Prog Clin Biol Res; 1988; 260():89-100. PubMed ID: 2966408
[No Abstract] [Full Text] [Related]
16. LH-RH analogue treatment for advanced prostate cancer.
Alcini E; D'Addessi A; Destito A; Grasso G
Am J Clin Oncol; 1988; 11 Suppl 2():S120-2. PubMed ID: 2977266
[TBL] [Abstract][Full Text] [Related]
17. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
Beacock CJ; Buck AC; Zwinck R; Peeling WB; Rees RW; Turkes A; Walker K; Griffiths K
Br J Urol; 1987 May; 59(5):436-42. PubMed ID: 2954605
[TBL] [Abstract][Full Text] [Related]
18. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
[TBL] [Abstract][Full Text] [Related]
19. Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group.
Soloway MS; Chodak G; Vogelzang NJ; Block NL; Schellhammer PF; Smith JA; Scott M; Kennealey G; Gau TC
Urology; 1991 Jan; 37(1):46-51. PubMed ID: 1824732
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with advanced cancer of the prostate: phase III trial, zoladex against castration; a study of the British Prostate Group.
Turkes AO; Peeling WB; Griffiths K
J Steroid Biochem; 1987; 27(1-3):543-9. PubMed ID: 2961938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]